Journal
BRITISH JOURNAL OF CANCER
Volume 104, Issue 10, Pages 1558-1563Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2011.140
Keywords
breast cancer; pharmacoepidemiology; tamoxifen; aromatase inhibitors; compliance; persistence
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- Canada Foundation for Innovation
Ask authors/readers for more resources
BACKGROUND: Non-compliance with oral treatment in oncology is an emerging health issue. For breast cancer (BC) patients, few data are available on compliance and persistence to tamoxifen in younger women and to aromatase inhibitors (AIs) as compared with tamoxifen in older women. METHODS: We constituted a cohort of 13 479 women with BC who received at least one prescription of tamoxifen or AI between 1998 and 2008, in the United Kingdom General Practice Research Database. Days covered by medication and treatment discontinuation were studied. Time to treatment discontinuation was calculated using Kaplan-Meier estimates. RESULTS: Overall, 18.9% (95% CI: 15.1-23.0) of women on AIs as compared with 31.0% (95% CI: 29.6-32.2) of women on tamoxifen had discontinued their treatments within the first 5 years (P<0.001). This rate raised to 50.7% (95% CI: 43.0-57.9) among the 416 women under 40 years receiving tamoxifen as initial hormonal therapy. Among older women, treatment discontinuation was less frequent for AIs as compared with tamoxifen (P<0.001). Among women on AI therapy, 14% of them (n = 374) had switched treatments. CONCLUSION: Among older women, the real-life patterns of use of AI show high rates of compliance. In younger women, tamoxifen is prematurely discontinued for half of patients. British Journal of Cancer (2011) 104, 1558-1563. doi: 10.1038/bjc.2011.140 www.bjcancer.com Published online 26 April 2011 (C) 2011 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available